Filtered By:
Source: Expert Review of Hematology
Condition: Thrombosis
Management: Marketing
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Betrixaban - the next direct factor Xa inhibitor?
Authors: Thoenes M, Minguet J, Bramlage K, Bramlage P, Ferrero C
Abstract
INTRODUCTION: Venous thromboembolism is a major global health burden. Since the 1930s, prevention of stroke and pulmonary embolism in these patients has been achieved using conventional anticoagulants, such as heparin and warfarin. However, in recent years, four direct non-vitamin K antagonist oral anticoagulants (DOACs) have entered the market as alternative treatment options. Betrixaban is a fifth DOAC looking to gain marketing approval in the near future, and may have several potentially beneficial properties. Areas covered: Here, we outli...
Source: Expert Review of Hematology - November 6, 2016 Category: Hematology Tags: Expert Rev Hematol Source Type: research
